Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Pliant Therapeutics Q3 2026 10-Q: 61.99M Shares Outstanding

Pliant Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026.

Nitish Kishor | 12 November 2026

Andretti Acquisition Corp. II Reports Q3 2026 Results

Andretti Acquisition Corp. II filed its Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, and reporting continued trust account activity and a significant reduction in redeemable shares outstanding.

Nitish Kishor | 12 November 2026

Candel Therapeutics Files Q3 2026 Report, 78.4M Shares Out

Candel Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 12, 2026, covering the fiscal quarter ended September 30, 2026.

Vinay Lochav | 12 November 2026

System1 Announces NYSE Delisting and Q3 2026 Results

System1, Inc. filed a current report on November 12, 2026, disclosing its voluntary intention to delist its Class A Common Stock from the New York Stock Exchange and announcing financial results for the quarter ended September 30, 2026.

Shwetambri Chauhan | 12 November 2026

Hour Loop Q3 2026: Revenue $32M, Net Income $422K

Hour Loop, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, reporting net income and year-over-year revenue growth for the nine-month period.

Manish Choudhary | 12 November 2026

Flowers Foods 10-Q: 40 Weeks Ended October 10, 2026

Flowers Foods, Inc. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 12, 2026, covering the fiscal period ended October 10, 2026.

Vinay Lochav | 12 November 2026

System1 Posts $134M Nine-Month Loss, Goodwill Impairment

System1, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 12, 2026, reporting a net loss of $134.4 million for the first nine months of the year alongside significant asset impairments.

Shwetambri Chauhan | 12 November 2026

Parabilis Medicines Files Q3 2026 Report With 123.7M Shares Out

Parabilis Medicines, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026.

Vinay Lochav | 12 November 2026

Evommune Q3 2026: Total Assets Rose to $278.3 Million

Evommune, Inc. (NYSE:EVMN) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, disclosing condensed consolidated financial statements and related disclosures.

Shwetambri Chauhan | 12 November 2026

Streamex Corp. Files Q3 2026 Earnings Results 8-K

Streamex Corp. filed a current report on Form 8-K on November 12, 2026, announcing the availability of its financial results for the third quarter ended September 30, 2026, including an earnings release and an earnings presentation.

Nitish Kishor | 12 November 2026
Support

Hi! How can we help you today?

Loading…